机构：[1]Department of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People's Hospital/The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 611130, China.[2]Chengdu Yunce Medical Biotechnology Co., Ltd., Chengdu 611135, China.[3]Division of Pulmonary Medicine, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou 325000, China.
Epstein-Barr virus (EBV), a ubiquitous human herpesvirus, has been robustly linked to the pathogenesis of nasopharyngeal carcinoma (NPC). The mechanism of EBV-induced NPC involves complex interactions between viral proteins and host cell pathways. This review aims to comprehensively outline the mechanism of EBV-induced NPC and the latest advances in targeted EBV vaccines for prophylaxis and treatment. This review explores the intricate molecular mechanisms by which EBV contributes to NPC pathogenesis, highlighting viral latency, genetic and epigenetic alterations, and immune evasion strategies. It emphasizes the pivotal role of key viral proteins, including EBNA1, LMP1, and LMP2A, in carcinogenesis. Subsequently, the discussion shifts towards the development of targeted EBV vaccines, including preventive vaccines aimed at preventing primary EBV infection and therapeutic vaccines aimed at treating diagnosed EBV-related NPC. The review underscores the challenges and future directions in the field, stressing the importance of developing innovative vaccine strategies and combination therapies to improve efficacy. This review synthesizes current insights into the molecular mechanisms of EBV-induced NPC and the development of EBV-targeted vaccines, highlighting the potential use of mRNA vaccines for NPC treatment.
基金：
This work was supported in part by the Science and technology project of the Health
Planning Committee of Sichuan and Chengdu (2020035 & 2021115 & 2024276); Joint Innovation Fund
of Chengdu Fifth People’s Hospital Affiliated to Chengdu University of Traditional Chinese Medicine
(LH202402003); Chengdu Municipal Health Commission School Joint Fund Project (WXLH202403256);
Xinglin Scholars Program of Chengdu University of Traditional Chinese Medicine (YYZX2021039);
Chengdu Fifth People’s Hospital Scientific Research Project (KYJJ2021-05) and Chengdu Fifth People’s
Hospital Teaching Reform Research Project (JGZX202214).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|3 区医学
小类|3 区免疫学3 区医学：研究与实验
最新[2025]版：
大类|3 区医学
小类|3 区免疫学3 区医学：研究与实验
第一作者：
第一作者机构：[1]Department of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People's Hospital/The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 611130, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Weiwei,Wang Chuang,Meng Yousheng,et al.EBV Vaccines in the Prevention and Treatment of Nasopharyngeal Carcinoma[J].Vaccines.2025,13(5):doi:10.3390/vaccines13050478.
APA：
Zhang Weiwei,Wang Chuang,Meng Yousheng,He Lang&Dong Mingqing.(2025).EBV Vaccines in the Prevention and Treatment of Nasopharyngeal Carcinoma.Vaccines,13,(5)
MLA：
Zhang Weiwei,et al."EBV Vaccines in the Prevention and Treatment of Nasopharyngeal Carcinoma".Vaccines 13..5(2025)
